As of March 2026, just 13 state Medicaid programs cover GLP-1 medications, including Ozempic, for obesity treatment: Delaware Kansas Massachusetts Michigan Minnesota Mississippi Missouri North Carolina Rhode Island Tennessee Utah Virginia Wisconsin Medicaid programs in California, New Hampshire, Pennsylvania, and South Carolina all recently ended obesity drug coverage, citing the steep cost of these medications
55 Effect on Cardiovascular Health One of the significant causes of mortality among patients with MASLD is cardiovascular-related adverse events
10.1016/j.joca.2013.01.014 Osteoarthr
When selecting a supplier, prioritize those offering certificates of analysis, HPLC purity verification (95%+), and proper cold-chain shipping to maintain peptide integrity
Rajguru will carefully review your health history, current symptoms, and lifestyle habits